NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Phentermine with topiramate for the treatment of obesity and overweight

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
 Vivus (phentermine with topiramate) Patient/carer groups Action Heart Afiya Trust Beat Black Health Agency Blood Pressure Association British Cardiac Patients Association Counsel and Care Diabetes UK Equalities National Council Healthier Weight Centres Heart Care Partnership UK HEART UK Insulin Dependent Diabetes Trust Muslim Council of Britain Muslim Health Network Network of Sikh Organisations UK National Obesity Forum Overweight and Obesity Organisation 	 Board of Community Health Councils in Wales British Cardiovascular Industry Association British National Formulary Care Quality Commission Commissioning Support Appraisals Services Department of Health, Social Services and Public Safety for Northern Ireland Diabetes UK Cymru Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Clinical Obesity Group NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium
 South Asian Health Foundation Specialised Healthcare Alliance Surya Foundation Weight Concern 	Possible comparator manufacturers Arena Pharmaceuticals (lorcaserin) Roche Products (Orlistat)
 Professional groups Association for the Study of Obesity Association of British Clinical Diabetologists Association of Diabetes Specialist Nurses British Association for Nursing in Cardiac Care British Association for Services to the Elderly 	 Relevant research groups British Society for Cardiovascular Research (BCS affiliated) Cardiovascular Diseases Specialist Library Cochrane Heart Group Cochrane Peripheral Vascular Disease Group Cochrane Public Health Group

Provisional matrix for the proposed technology appraisal of phentermine with topiramate for the treatment obesity and overweight

Issue date: January 2012

Consultees	Commentators (no right to submit or appeal)
 British Cardiovascular Intervention Society British Cardiovascular Society British Dietetic Association British Geriatric Society British Heart Foundation British Hypertension Society British Nutrition Foundation Diabetes Monitoring Forum Dieticians in Obesity Management Faculty of Public Health Medicine National Centre for Eating Disorders National Heart Forum UK Primary Care Cardiovascular Society Primary Care Diabetes UK Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal Society of Medicine Society for Endocrinology Society for Vascular Technology Society for Vascular Nurses The Nutrition Society The Obesity Management Association United Kingdom Clinical Pharmacy Association Vascular Society Others Cwm Taf Health Board Department of Health NHS Hounslow 	CORDA Diabetes Foundation Diabetes Research & Wellness Foundation MRC Clinical Trials Unit National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust — Cardiovascular Research Initiative Evidence Review Group Evidence Review Group National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups tbc
Welsh Government	

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of phentermine with topiramate for the treatment obesity and overweight

Issue date: January 2012

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.